On September 28, 2020, new rules for determining the maximum size of wholesale and retail markups to the actual selling prices of manufacturers of medicines included in the vital and essential drugs list came into force.
On September 8, 2020, the Administrative Regulations of the Federal Service for Surveillance in Healthcare on the provision of state services for issuing a permit for the retail sale of medicinal products for medical use remotely, approved by order of the Federal Service for Surveillance in Healthcare N 5161 (hereinafter referred to as the “Administrative Regulations”), came into force.
Decree of the Government of Russia dated July 4, 2020 N 982 establishes that from January 1, 2021, such legal acts as:
On August 31, 2020, the decree of the Ministry of Health of the Russian Federation of May 15, 2020, N 450n “On approval of the procedure for determining the initial (maximum) contract price, the price of a contract concluded with a single supplier (contractor, performer), and the initial unit price of goods” came into force, work, services in the procurement of medical products.
The order of putting drugs for medical use into circulation until January 1, 2021, has been approved
By the Decree of the Government of Russia dated June 30, 2020 N 955, the order of the introduction into the circulation of medicinal products for medical use until January 1, 2021, were approved.
- The Ministry of Health has developed a procedure for maintaining a register of citizens entitled to subsidized medicines
- Supervision over the circulation of medicinal products and medical devices have been included in the experiment on pre-trial online appeal of decisions of control authorities
- Federal Law No. 206-FZ of July 13, 2020 amended the legislation on the provision of citizens with medicines, medical devices and specialized health food products
- Liability for non-repatriation of foreign currency earnings has been changed
Earlier articles
Latest news
Digest of the Russian pharmaceutical industry in the 2nd quarter of 2023
28-07-2023
Among the most important changes in the regulation of the Russian pharmaceutical industry in the 2nd quarter of 2023, are the following: :
Digest of regulation of international trade in Russia in the 1st quarter of 2023
17-05-2023
Among the most important changes in the regulation of foreign economic activity in the 1st quarter of 2023, the following can be distinguished:
Digest of the Russian pharmaceutical industry in the 1st quarter of 2023
12-05-2023
Among the most important changes in the regulation of the Russian pharmaceutical industry in the 1st quarter of 2023, the following can be distinguished:
Roman Shabrov, attorney at law and partner at BRACE commented on the case of an anticompetitive agreement in the antiseptic market
21-02-2022
Roman Shabrov, partner at BRACE commented for Pharmaceutical Bulletin magazine on the case of an anti-competitive agreement on the Chlorhexedine antiseptic market, identified by the FAS Russia, the resolution of which was appealed by the companies held liable.
The Eurasian Economic Commission recalls the registration of medicines according to the rules of the EAEU
11-08-2021
In July 2021, the Eurasian Economic Commission issued an update that from July 1, 2021, medicinal products should be registered according to the unified rules of the EAEU. These rules were approved by the Decision of the Council of the Economic Commission dated 03.01.2017 No. 78 “On the rules for registration and examination of medicines for medical use”. At the same...
The Ministry of Health has allowed the use of personal medicines of patients in inpatient treatment
11-08-2021
Recall that earlier by Appendix No. 5 to the Rules of Compulsory Medical Insurance, approved by order of the Ministry of Health of the Russian Federation No. 108n dated February 28, 2019, determining the coefficients of the amount of non-payment or incomplete payment of the costs of a medical organization for the provision of medical care as a basis for...
